

## Vitamin D with Calcium reduces mortality: patient level pooled analysis of 70,528 patients from eight major vitamin D trials

Article (Unspecified)

Rejnmark, Lars, Avenell, Alison, Masud, Tahir, Anderson, Frazer, Meyer, Haakon E, Sanders, Kerrie M, Salovaara, Kari, Cooper, Cyrus, Smith, Helen E, Jacobs, Elizabeth T, Torgerson, David, Jackson, Rebecca D, Manson, JoAnn E, Brixen, Kim, Mosekilde, Leif et al. (2012) Vitamin D with Calcium reduces mortality: patient level pooled analysis of 70,528 patients from eight major vitamin D trials. *Journal of Clinical Endocrinology and Metabolism*, 97 (8). pp. 2670-2681. ISSN 0021-972X

This version is available from Sussex Research Online: <http://sro.sussex.ac.uk/id/eprint/40400/>

This document is made available in accordance with publisher policies and may differ from the published version or from the version of record. If you wish to cite this item you are advised to consult the publisher's version. Please see the URL above for details on accessing the published version.

### **Copyright and reuse:**

Sussex Research Online is a digital repository of the research output of the University.

Copyright and all moral rights to the version of the paper presented here belong to the individual author(s) and/or other copyright owners. To the extent reasonable and practicable, the material made available in SRO has been checked for eligibility before being made available.

Copies of full text items generally can be reproduced, displayed or performed and given to third parties in any format or medium for personal research or study, educational, or not-for-profit purposes without prior permission or charge, provided that the authors, title and full bibliographic details are credited, a hyperlink and/or URL is given for the original metadata page and the content is not changed in any way.

## Vitamin D with Calcium Reduces Mortality: Patient Level Pooled Analysis of 70,528 Patients from Eight Major Vitamin D Trials

Lars Rejnmark, Alison Avenell, Tahir Masud, Frazer Anderson, Haakon E. Meyer, Kerrie M. Sanders, Kari Salovaara, Cyrus Cooper, Helen E. Smith, Elizabeth T. Jacobs, David Torgerson, Rebecca D. Jackson, JoAnn E. Manson, Kim Brixen, Leif Mosekilde, John A. Robbins, Roger M. Francis, and Bo Abrahamsen\*

**Introduction:** Vitamin D may affect multiple health outcomes. If so, an effect on mortality is to be expected. Using pooled data from randomized controlled trials, we performed individual patient data (IPD) and trial level meta-analyses to assess mortality among participants randomized to either vitamin D alone or vitamin D with calcium.

**Subjects and Methods:** Through a systematic literature search, we identified 24 randomized controlled trials reporting data on mortality in which vitamin D was given either alone or with calcium. From a total of 13 trials with more than 1000 participants each, eight trials were included in our IPD analysis. Using a stratified Cox regression model, we calculated risk of death during 3 yr of treatment in an intention-to-treat analysis. Also, we performed a trial level meta-analysis including data from all studies.

**Results:** The IPD analysis yielded data on 70,528 randomized participants (86.8% females) with a median age of 70 (interquartile range, 62–77) yr. Vitamin D with or without calcium reduced mortality by 7% [hazard ratio, 0.93; 95% confidence interval (CI), 0.88–0.99]. However, vitamin D alone did not affect mortality, but risk of death was reduced if vitamin D was given with calcium (hazard ratio, 0.91; 95% CI, 0.84–0.98). The number needed to treat with vitamin D plus calcium for 3 yr to prevent one death was 151. Trial level meta-analysis (24 trials with 88,097 participants) showed similar results, *i.e.* mortality was reduced with vitamin D plus calcium (odds ratio, 0.94; 95% CI, 0.88–0.99), but not with vitamin D alone (odds ratio, 0.98; 95% CI, 0.91–1.06).

**Conclusion:** Vitamin D with calcium reduces mortality in the elderly, whereas available data do not support an effect of vitamin D alone. (*J Clin Endocrinol Metab* 97: 0000–0000, 2012)

During the last decade, there has been increasing recognition of the potential role of vitamin D in a large number of tissues, where vitamin D receptors have been identified. Thus, maintenance of adequate vitamin D status may be necessary for many physiological functions, beyond that of the classical actions of vitamin D on bone and mineral metabolism. Cross-sectional and longitudinal studies have linked reduced vitamin D status with a number of cancers, adverse cardiovascular and immunological outcomes, and increased all-cause mortality, although some observational data have suggested either U-shaped or reverse J-shaped relationships (1–3).

A meta-analysis of randomized controlled trials of vitamin D supplementation published in 2007 found that vitamin D reduced all-cause mortality by 7% (relative risk, 0.93; 95% CI, 0.87–0.99) (4). However, three subsequent meta-analyses using updated searches and different study inclusion criteria failed to show a statistically significant effect of vitamin D alone on mortality (2, 5, 6), although two of the studies did show a reduced mortality if vitamin D was given together with calcium (5, 6). Study level meta-analyses using summary data may be adequate when estimating a single treatment effect or investigating study

level characteristics but may lead to biased assessments and have limitations in explaining heterogeneity. To investigate whether treatment effects are related to patient characteristics, individual patient data (IPD) analyses offer advantages and have greater statistical power than study level meta-analyses (7).

We recently published results of an IPD level meta-analysis showing that vitamin D in doses of 10–20  $\mu\text{g}/\text{d}$  given alone were not effective in fracture prevention, but when given with calcium reduced fracture incidence (8). In the present study, we aimed to investigate effects of vitamin D supplementation, given either alone or with calcium, on all-cause mortality using both IPD level and study level meta-analysis methodologies.

## Materials and Methods

### Searching and selection criteria

As previously detailed, we undertook a systematic literature search for publications between 1966 and 2008 in Medline, Embase, and the Cochrane Central Register of Controlled Trials on the effects of vitamin D treatment on the risk of fracture (8). No language restrictions were applied. We included only randomized (individual or cluster) controlled studies in which cholecalciferol (vitamin D<sub>3</sub>) or ergocalciferol (vitamin D<sub>2</sub>) was given in at least one intervention arm and with one arm without vitamin D. For the IPD analysis, we excluded studies with less than 1000 participants (nine trials) due to concerns that studies with fewer participants, although contributing additional cases, would also further reduce the mass of shared study variables for aggregated analysis. The search revealed 11 eligible studies (9–19). For the present analysis, we updated our search to January 2011 and included the MeSH terms: [death, mortality], thereby identifying two further eligible studies (20, 21). Five study groups were unwilling or unable to provide patient level data (9, 10, 12, 16, 17), leaving eight studies for IPD analysis (Table 1). All studies had incident fractures as the primary endpoint, whereas data on death were collected as secondary endpoints during follow-up (14, 15, 18–20) and/or by the use of national registers of vital statistics (11, 13, 15, 19, 21).

### Analytical approach

We defined base models using unconditional logistic regression incorporating age and sex, which we expected *a priori*

to contribute to variation in mortality. We also included data on incident major osteoporotic fracture during the study, *i.e.* fractures at the hip or spine because mortality is known to be increased after such fractures, and information on the use of postmenopausal hormone replacement therapy (HRT) and bisphosphonates. Analysis on mortality was performed using a stratified Cox regression model, with the clinical study as stratum, thereby ensuring that like was compared with like, because the inference is based on the randomization of patients within each trial. We added treatment allocation and interaction terms to this model to study effects of vitamin D *vs.* no vitamin D supplements on risk of death. Interaction terms studied included age, sex, and daily dose of vitamin D. In studies with intermittent (monthly or yearly) administration of vitamin D, an equivalent daily dose was calculated. In all analyses, observations were truncated after 36 months (1095 d) because few of the studies provided substantial data beyond this time point. However, to evaluate the effect of interventions during the entire duration of trials, we also performed logistic regression analyses with treatment allocation added to the base model. All analyses were performed using an intention-to-treat approach including all randomized participants.

### Prespecified subanalyses

Three prespecified analyses were performed:

1. Because ergocalciferol may have a shorter half-life than cholecalciferol and lower systemic availability if injected *im* (22), we studied the effects of cholecalciferol separately and addressed the impact of vitamin D dose on mortality by regrouping the Smith *et al.* (18) study (average, 20.5  $\mu\text{g}$  ergocalciferol/d) with 10- $\mu\text{g}$  cholecalciferol studies.
2. Whether vitamin D was administered alone or with calcium supplements (CaD) and whether daily *vs.* intermittent administration affected results.
3. In the RECORD study, one of the treatment arms had calcium as stand-alone treatment, *i.e.* without concomitant vitamin D (15). *A priori*, participants randomized to the calcium-alone group were considered as belonging to the placebo/non-vitamin D group. However, because recent studies have suggested detrimental effects of calcium-alone treatment (23), analyses were also performed in which participants randomized to the calcium-alone group were removed from the analyses.

### Sensitivity

To assess whether our conclusions would have been modified by failure to include one or more individual studies, we per-

Department of Endocrinology and Internal Medicine (L.R., L.M.), Aarhus University Hospital, 8000 Aarhus, Denmark; Health Services Research Unit (A.A.), University of Aberdeen, Aberdeen AB24 2TZ, United Kingdom; Geriatric Medicine (T.M.), Nottingham University Hospitals, Nottingham NG1 5DU, United Kingdom; Institute of Clinical Research (T.M., K.B., B.A.), University of Southern Denmark, 5000 Odense, Denmark; Geriatric Medicine (F.A.), Developmental Origins of Health and Disease Research Division, University of Southampton School of Medicine, Southampton SO17 1BJ, United Kingdom; Division of Epidemiology (H.E.M.), Norwegian Institute of Public Health, 0456 Oslo, Norway; Department of Community Medicine (H.E.M.), University of Oslo, 0316 Oslo, Norway; NorthWest Academic Centre (K.M.S.), Department of Medicine, University of Melbourne and Western Health, Victoria 3052, Australia; Bone and Cartilage Research Unit (K.S.), University of Eastern Finland, 70210 Kuopio, Finland; Department of Orthopedics, Traumatology, and Handsurgery (K.S.), Kuopio University Hospital, 70211 Kuopio, Finland; Medical Research Council Lifecourse Epidemiology Unit (C.C.), University of Southampton and National Institute for Health Research Biomedical Research Unit in Musculoskeletal Science, University of Oxford, Oxford OX1 2JD, United Kingdom; Primary Care and Public Health (H.E.S.), Brighton and Sussex Medical School, Brighton BN19PH, United Kingdom; Mel and Enid Zuckerman College of Public Health and the Arizona Cancer Center (E.T.J.), University of Arizona, Tucson Arizona 85721; York Trials Unit (D.T.), University of York, York YO1 05DD, United Kingdom; Division of Endocrinology, Diabetes, and Metabolism (R.D.J.), College of Medicine, The Ohio State University, Columbus, Ohio 43210; Department of Medicine (J.E.M.), Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115; Endocrinology (K.B.), Odense University Hospital, DK-5000 Odense, Denmark; Internal Medicine (J.A.R.), University of California Davis, Sacramento, California 95817; Institute for Ageing and Health (R.M.F.), Newcastle University, Campus for Ageing and Vitality, Newcastle upon Tyne NE4 5PL, United Kingdom; and Department of Medicine F (B.A.), Copenhagen University Hospital Gentofte, DK-2900 Hellerup, Denmark

**TABLE 1.** Characteristics of the eight randomized controlled trials included in the IPD analysis and 16 additional studies included in the trial level meta-analysis

First author, year (Ref.)	Patient category; total no. of included participants (% females); median age (IQR) or mean $\pm$ sd; place of study	Randomization and duration	Study arms; no. of participants in each arm/total no. of deaths during the entire period of follow-up <sup>a</sup> (no. of deaths during the first 36 months of follow-up <sup>b</sup> )
Studies included in IPD analysis			
Meyer, 2002 (11)	Nursing home residents; n = 1,144 (75.9%); age, 85 (81–90) yr; Norway	Q, 24 months, double-blind	Daily oral 10 $\mu$ g D <sub>3</sub> , 569/246 (246), vs. placebo, 575/245 (245)
Larsen, 2004 (13)	Community-dwelling aged $\geq$ 66 yr; n = 9,605 (60.1%); age, 74 (70–79) yr; Denmark	C, 42 months, open-label	Daily oral 10 $\mu$ g D <sub>3</sub> + 1000 mg Ca, 4,957/832 (715), vs. no treatment, 4,648/839 (705)
Porthouse, 2005 (14)	GP patients with risk factors for fracture; n = 3,314 (100%); age, 76 (73–80) yr; UK	I, 18–42 (median, 22.5) months, open-label	Daily oral 20 $\mu$ g D <sub>3</sub> + 1000 mg Ca, 1,321/57 (57), vs. leaflet, 1,993/68 (67)
Grant (RECORD), 2005 (15)	Previous osteoporotic fracture; n = 5,292 (84.7%); age, 77 (73–81) yr; UK	I, 24–62 (median, 30.4) months, double-blind	Four groups with daily oral dose: 1) 20 $\mu$ g D <sub>3</sub> + 1000 mg Ca, 1,306/221 (161); 2) 20 $\mu$ g D <sub>3</sub> , 1,343/217 (167); 3) 1000 mg Ca, 1,311/243 (198); 4) double placebo, 1,332/217 (172)
Smith, 2007 (18)	GP patients presenting for influenza vaccination; n = 9,440 (53.9%); age, 79 (77–83) yr; UK	I, up to 36 (median, 36.0) months, double-blind	Once a year im 300,000 IU D <sub>2</sub> , 4,727/316 (290), vs. placebo, 4,713/312 (291) (equal to an average D <sub>2</sub> dose of 20.5 $\mu$ g/d)
LaCroix (WHI), 2009 (19) <sup>c</sup>	Community-based postmenopausal women; n = 36,282 (100%); age, 62 (57–68) yr; USA	I, median, 85.4 months, double-blind	Daily oral 10 $\mu$ g D <sub>3</sub> + 1000 mg Ca, 18,176/755 (180), vs. placebo, 18,106/825 (220)
Sanders, 2010 (20) <sup>e</sup>	Community-dwelling aged $\geq$ 70 yr; n = 2,256 (100%); age, 76 (73–80) yr; Australia	I, up to 60 (median, 36) months, double-blind	Once a year oral 500,000 IU D <sub>3</sub> , 1,131/46 (39), vs. placebo, 1,125/54 (46) (equal to an average D <sub>3</sub> dose of 34 $\mu$ g/d)
Salovaara (OSTPRE-FPS), 2010 (21) <sup>d</sup>	Community-dwelling women aged 65–71 yr; n = 3,195 (100%); age, 67 (66–69) yr; Finland	I, up to 36 months; mean follow-up time, 3.01 (sd, 0.22) yr, open-label	Daily oral 20 $\mu$ g D <sub>3</sub> + 1000 mg Ca, 1,586/15 (15), vs. no treatment, 1,609/18 (18)
Additional medium- and large-sized (>500 participants) studies included in trial level meta-analysis			
Chapuy, 1994 (9)	Nursing home residents; n = 3,270 (100%); age, 84 $\pm$ 6 yr; France	I, up to 36 months, double-blind	Daily oral 20 $\mu$ g D <sub>3</sub> + 1200 mg Ca, 1,634/601, vs. placebo, 1,636/597
Lips, 1996 (10)	Living independently, in apartments/homes for elderly persons aged $\geq$ 70 yr; n = 2,578 (74%); age, 80 $\pm$ 6 yr; The Netherlands	I, up to 42 months, double-blind	Daily oral 10 $\mu$ g D <sub>3</sub> , 1,291/223, vs. placebo, 1,287/251
Chapuy, 2002 (27)	Ambulatory institutionalized women; n = 583 (100%); age, 85 $\pm$ 7 yr; France	I, up to 24 months, double-blind	Daily oral 20 $\mu$ g D <sub>3</sub> + 1200 mg Ca, 393/71, vs. placebo, 190/45

(Continued)

TABLE 1. Continued

First author, year (Ref.)	Patient category; total no. of included participants (% females); median age (IQR) or mean $\pm$ sd; place of study	Randomization and duration	Study arms; no. of participants in each arm/total no. of deaths during the entire period of follow-up <sup>a</sup> (no. of deaths during the first 36 months of follow-up <sup>b</sup> )
Trivedi, 2003 (12)	Community-dwelling aged $\geq$ 65 yr; n = 2,686 (24%); age, 75 $\pm$ 5 yr; UK	I, up to 60 months, double-blind	Every fourth month, oral 100,000 IU D <sub>3</sub> , 1,345/224, vs. placebo, 1,341/247 (equal to an average D <sub>3</sub> dose of 21 $\mu$ g/d)
Flicker, 2005 (28)	Nursing home residents; n = 625 (95%); age, 83 $\pm$ 8 yr; Australia	I, up to 24 months, double-blind	Daily oral 600 mg Ca + D <sub>2</sub> , initially 10,000 IU weekly followed by 25 $\mu$ g/d, 313/76, vs. placebo, 312/85
Law, 2006 (16) <sup>f</sup>	Nursing home residents; n = 2,641 (76%); mean age, 85 yr; UK	C, median, 10 (IQR, 7–14) months, open-label	Every third month, oral 100,000 IU D <sub>2</sub> , 1,252/247, vs. placebo, 1,389/229 (equal to an average D <sub>2</sub> dose of 28 $\mu$ g/d)
Lyons, 2007 (17)	Nursing home residents; n = 3,440 (76%); age, 84 $\pm$ 8 yr; UK	I, up to 36 months, double-blind	Every fourth month, oral 100,000 IU D <sub>2</sub> , 1,673/713, vs. placebo, 1,670/715 (equal to an average D <sub>2</sub> dose of 21 $\mu$ g/d)
Small-sized studies (<500 participants) included in trial level meta-analysis			
Baeksgaard, 1998 (29)	Healthy women aged 58–67 yr; n = 240 (100%); mean age, 62 yr; Denmark	I, 24 months, double-blind	Daily oral 14 $\mu$ g D <sub>3</sub> + 1000 mg Ca, 160/1, vs. placebo, 80/1
Krieg, 1999 (43)	Institutionalized women aged 62–98 yr; n = 248 (100%); age, NA; Switzerland	I, 24 months, open-label	Daily oral 22 $\mu$ g D <sub>3</sub> + 1000 mg Ca, 124/21, vs. no treatment, 124/26
Komulainen, 1999 (44)	Early postmenopausal women; n = 458 (100%); mean age, 53 yr (Finland)	I, 60 months, open-label	Four treatment groups with daily oral: 1) HRT, 115/1; 2) 7.5 $\mu$ g D <sub>3</sub> (only 2.5 $\mu$ g/d during the fifth year), 112/0; 3) HRT + D <sub>3</sub> as above, 116/1; 4) placebo, 115/1
Latham, 2003 (30)	Frail elderly aged >65 yr; n = 243 (53%); age, 79 $\pm$ 7 yr; New Zealand	I, 6-month follow-up, double-blind	Single oral dose 300,000 IU D <sub>3</sub> , 121/11, vs. placebo, 122/3
Avenell, 2004 (45)	Aged >70 yr and a history of an osteoporotic fracture within the last 10 yr; n = 134 (82%); age, 77 $\pm$ 5 yr; UK	I, 12 months, open-label	Daily oral 20 $\mu$ g D <sub>3</sub> + 1000 mg Ca, 99/1, vs. no treatment, 35/1
Harwood, 2004 (46)	Elderly with a recent hip fracture; n = 150 (100%); age, 81 (67–92) yr; UK	I, 12 months, open-label	Four study groups: 1) single injection of D <sub>2</sub> 300,000 IU, 38/7; 2) single injection D <sub>2</sub> 300,000 IU + 1000 mg/d Ca, 36/11; 3) oral D <sub>3</sub> 20 $\mu$ g/d + 1000 mg/d Ca, 39/6; 4) no treatment, 37/5
Meier, 2004 (47)	Healthy community dwelling aged 33–78 yr; n = 55 (65%); age, NA; Germany	I, 12 months, open-label	Daily oral 12.5 $\mu$ g D <sub>3</sub> + 500 mg Ca, 30/0, vs. no treatment, 25/1
Brazier, 2005 (31)	Women >65 yr with plasma 25OHD <30 nmol/liter; n = 192 (100%); age, 75 $\pm$ 7 yr; France	I, 12 months, double-blind	Daily oral 20 $\mu$ g D <sub>3</sub> + 1000 mg Ca, 95/3, vs. placebo, 97/1

(Continued)

**TABLE 1.** Continued

First author, year (Ref.)	Patient category; total no. of included participants (% females); median age (IQR) or mean ± sd; place of study	Randomization and duration	Study arms; no. of participants in each arm/total no. of deaths during the entire period of follow-up <sup>a</sup> (no. of deaths during the first 36 months of follow-up <sup>b</sup> )
Schleithoff, 2006 (32)	Patients with congestive heart failure; n = 123 (17%); median age, 55 yr; Germany	I, 9 months, double-blind	Daily oral 50 μg D <sub>3</sub> + 500 mg Ca, 61/7, vs. 500 mg Ca, 62/6

I, Individually randomized; Q, quasi-randomized by birth date; C, cluster randomized; IQR, interquartile range; 25OHD, 25-hydroxyvitamin D; GP, general practice; Ca, calcium supplement; NA, not available. To convert micrograms of vitamin D into international units, multiply by 40.

<sup>a</sup> Total number of deaths during the entire follow-up period, *i.e.* not restricted to the 36 months of follow-up used in the IPD analysis.

<sup>b</sup> Data only available for studies included in the IPD analysis.

<sup>c</sup> Number of deaths is based on the WHI Investigator Data Set updated on September 12, 2005 (released on December 21, 2006), in which slightly more (n = 29) deaths have been recorded than in the original trial report.

<sup>d</sup> Number of deaths is based on an updated data extraction (October, 2010) from the Finnish National Population Register in which slightly more (n = 5) deaths have been recorded than in the original trial report.

<sup>e</sup> Number of deaths in the original trial report was based on subjects who died while actively participating, whereas the number of deaths stated in the table is based on treatment allocation independently of whether subjects participated actively or not in the study.

<sup>f</sup> Adjustments to the number of participants (1762 vs. 1995) with outcomes, and denominators in study were made using an intraclass correlation coefficient of 0.026—see Sensitivity section for further explanations.

formed an influence analysis in which studies were removed one by one. To evaluate whether the lack of data from trials not included in the IPD analysis affected results, we performed a trial level meta-analysis including all available studies (n = 24) as detailed in Table 1. Number of deaths by treatment allocation up to 3 yr in the study by Chapuy *et al.* (9) was reported by personal communication (Prof. P. Meunier, July 2010). In the cluster randomized trial by Law *et al.* (16), adjustments to the number of participants with outcomes and denominators were made using an intraclass correlation coefficient of 0.026 derived from Dyer *et al.* (24) using methods described by Higgins and Green (25). All meta-analyses were performed stratified by whether vitamin D was administered alone or in combination with calcium and without the assumption of a common among-study variance component across subgroups. The manuscript was prepared in accordance with the PRISMA guidelines (26). Analyses were undertaken using SPSS version 15 (SPSS Inc., Chicago, IL) and Comprehensive Meta-analysis version 2.2 (Biostat, Englewood, NJ). All tests were two-tailed. We considered *P* < 0.05 as significant.

**Results**


**IPD analyses**

Our IPD analysis included 70,528 randomized participants (86.8% females) aged 48–103 (median, 70; interquartile range, 62–77) yr. A total of 27,345 were randomized to CaD and 7,771 to vitamin D alone, whereas 35,412 received placebo/no vitamin D.


**Defining the base model**

During the 36 months of follow-up, 3832 (5.4%) study participants died, and 1139 (1.6%) sustained an osteoporotic fracture at the hip or spine. At baseline, 970 (1.4%)

reported the use of bisphosphonates. Among females, 20,402 (33.9%) were treated with HRT. This was mainly due to the high proportion of HRT users in the Women’s Health Initiative (WHI) (50.7%) and the OSTPRE-FPS (48.5%) studies, whereas the frequency of HRT use in the other studies was low (2.3%). After mutual adjustments, the risk of death was significantly associated with increasing age [hazard ratio (HR) per decade, 1.87; 95% CI, 1.78–1.96], male sex (HR, 1.52; 95% CI, 1.41–1.64), and an incident major osteoporotic fracture during follow-up (HR, 1.47; 95% CI, 1.27–1.69), whereas mortality was



**FIG. 1.** IPD analysis on survival in participants randomized to vitamin D with or without calcium supplements compared with placebo/no supplements. Data represent adjusted HR (95% CI).



**FIG. 2.** IPD analysis on survival in participants randomized to vitamin D alone (*left*) or vitamin D with calcium (*right*) vs. placebo/no supplements. For the RECORD study, participants treated with calcium without concomitant vitamin D ( $n = 1311$ ) were excluded, whereas the placebo group ( $n = 1332$ ) was included in both analyses. Data represent adjusted HR (95% CI). \*,  $P < 0.05$ .

not significantly affected by use of HRT (HR, 0.88; 95% CI, 0.75–1.04) or bisphosphonates (HR, 0.60; 95% CI, 0.32–1.10).

Differences in mortality rates were not fully explained by differences in age, sex, number of incident major osteoporotic fractures, or treatment with bisphosphonates or HRT. Accordingly, analyses were performed adjusted for age, sex, incident major osteoporotic fractures, and use of bisphosphonates or HRT and stratified by study.

### Effects of vitamin D supplementation with or without calcium on risk of death

Within the group of participants randomized to vitamin D with or without calcium ( $n = 35,116$ ), 1,870 (5.3%) died during follow-up, whereas death occurred in 1,962 (5.5%) of the participants not allocated to vitamin D (HR<sub>crude</sub>, 0.94; 95% CI, 0.88–1.00). After adjustments, risk of death was reduced by 7% (HR, 0.93; 95% CI, 0.88–0.99) during the 3 yr of follow-up in participants randomized to vitamin D with or without calcium (Fig. 1). Visual inspection of the survival curve (Fig. 1) indicates that risk started to diverge quite quickly. However, although risk estimates were reduced in the group of vitamin D-treated participants, risk of death did not differ significantly between groups after 12 months (HR, 0.96; 95% CI, 0.86–1.08) or 24 months (HR, 0.94; 95% CI, 0.87–1.02) of treatment.

Statistically significant interaction terms were whether vitamin D was coadministered with calcium ( $P < 0.01$ ), whereas no significant interactions were found for sex ( $P = 0.83$ ), age ( $P = 0.08$ ), route of vitamin D administration ( $P = 0.65$ ), dosing interval ( $P = 0.98$ ), or treatment

at baseline with HRT ( $P = 0.46$ ) or bisphosphonates ( $P = 0.16$ ).

Mortality rates differed significantly between studies investigating the effects of vitamin D without calcium and studies on CaD (Table 1). On average, in the groups of untreated/placebo-treated participants, 4.4% died in the CaD trials, whereas 9.7% died in the studies on vitamin D alone ( $P < 0.01$ ).


### Effects of concomitant calcium administration

Restricting the analysis to studies with CaD supplementation (13–15, 19, 21), risk of death was significantly reduced among participants randomized to CaD (HR, 0.91; 95% CI, 0.84–0.98). Exclusion of participants from the placebo/non-vitamin D group who were treated with calcium alone ( $n = 1311$ ) did not change the results (HR, 0.92; 95% CI, 0.85–1.00;  $P < 0.05$ ) (Fig. 2).


On the other hand, restricting the analysis to the four studies on vitamin D alone (11, 15, 18, 20), risk of death did not differ according to treatment allocation (HR, 0.96; 95% CI, 0.87–1.06). Removal of the participants treated with calcium alone did not change the results (Fig. 2). Neither did vitamin D affect mortality if analyses were restricted to include only studies using cholecalciferol (HR, 0.94; 95% CI, 0.83–1.06).

### Dose-effect relationships

As shown in Fig. 3, no statistically significant dose-effect relationships were evident. Most estimates showed



**FIG. 3.** IPD analysis on dose-effect relationships of vitamin D treatment on risk of death. Note that none of the included studies used a daily dose between 10 and 20  $\mu\text{g}$ . All studies and stratified by whether vitamin D was provided alone (Vit D alone) or in combination with calcium (Vit D + calcium). Data represent adjusted HR (95% CI). The Smith study using an average daily dose of 20  $\mu\text{g}$  vitamin D<sub>2</sub> was regrouped into the low-dose (10  $\mu\text{g}/\text{d}$ ) group.



**FIG. 4.** Sensitivity analysis: influence of removing individual studies from the IPD analysis stratified by whether vitamin D (Vit D) was provided alone or in combination with calcium (Vit D + calcium). Data represent adjusted HR (95% CI). w/o, Without.

a reduced risk, but mortality was only significantly reduced in participants treated with a daily dose of 10  $\mu$ g vitamin D in combination with calcium (HR, 0.90; 95% CI, 0.83–0.99).

#### Daily vs. intermittent administration

Two studies provided data on intermittent (once-a-year) administration of either ergocalciferol (18) or cholecalciferol (20), which did not affect mortality (HR, 0.97; 95% CI, 0.83–1.12), whereas mortality was significantly decreased in participants randomized to receive daily supplements (HR, 0.93; 95% CI, 0.86–0.99). However, daily treatment with vitamin D without calcium did not affect mortality (HR, 0.95; 95% CI, 0.84–1.08), whereas mortality was reduced in participants randomized to daily CaD (HR, 0.91; 95% CI, 0.84–0.98).

#### Sensitivity analyses

Influence analyses showed only minor effects of exclusion of studies one by one (Fig. 4). Removal of the cluster randomized study by Larsen *et al.* (13) from the analysis on CaD trials did not change the results (HR, 0.88; 95% CI, 0.77–0.99).

In analyses not accounting for whether calcium was coadministered, mortality was borderline significantly reduced if analyses were restricted to only double-blind studies ( $P_{\text{interaction}} = 0.05$ ; HR, 0.92; 95% CI, 0.85–1.00) (11, 15, 18–20) and significantly reduced if analyses were further restricted to include only individually randomized double-blind studies ( $P_{\text{interaction}} = 0.02$ ; HR, 0.89; 95% CI, 0.81–0.98) (15, 18–20). Within the group of individually randomized double-blind studies, mortality was significantly reduced in response to CaD (HR, 0.83; 95% CI, 0.73–0.95) (15, 19), but not in response to vitamin D alone (HR, 0.96; 95% CI, 0.85–1.09) (15, 18, 20). Restricting analyses to include data from only open-label trials showed no significant effects on mortality (HR, 0.95; 95% CI, 0.86–1.05) (13, 14, 21).

#### Analyses not accounting for study duration

Although most included studies only provided data for a 3-yr intervention period, some studies had a longer duration (Table 1). Including all deaths occurring during studies ( $n = 5526$ ), logistic regression analysis (adjusted for indices included in the base model) showed no statistical significant effects on mortality in participants randomized to vitamin D with or without calcium (OR, 0.96; 95% CI, 0.90–1.01). However, stratification by coadministration of calcium ( $P_{\text{interaction}} < 0.01$ ) showed a reduced mortality in the CaD trials (OR, 0.93; 95% CI, 0.87–0.99), but not if vitamin D was given alone (OR, 0.98; 95% CI, 0.89–1.09).


#### Absolute risk reduction and numbers needed to treat

Because vitamin D alone was not shown to reduce mortality significantly, we did this analysis only for the CaD studies. Over 3 yr of follow-up, the absolute risk reduction was 0.66% (untreated event rate, 16 per 1000 person years), *i.e.* 151 persons should be treated for 3 yr to prevent one death.

#### Trial level meta-analysis

As shown in Fig. 5A, trial level meta-analysis of included studies from the IPD analysis showed results similar to the IPD analysis with a reduced risk of death in participants randomized to CaD (HR, 0.93; 95% CI, 0.87–0.99). Extending the analysis to include additional data from large- and medium-sized studies not included in the IPD analysis (Table 1) showed similar results (Fig. 5B). Finally, results were not changed by extending the analysis to include data from all studies shown in Table 1. This analysis included data on a total of 88,097 randomized participants, among whom 28,212 were included in 12 trials with vitamin D alone and 59,885 were included in 13 trials on CaD. Overall, mortality was significantly reduced ( $P = 0.04$ ) in participants randomized to treatment with vitamin D with or without calcium (OR, 0.95; 95% CI, 0.91–1.00). Stratification by coadministration of calcium showed reduced mortality in participants randomized to CaD (OR, 0.94; 95% CI, 0.88–0.99), but not in participants treated with vitamin D alone. Influence analyses with removal of studies one by one did not change risk estimates to any major degree, although mortality was no longer significantly reduced in response to CaD if the Larsen *et al.* (13) trial (HR, 0.94; 95% CI, 0.86–1.03) or the WHI (19) study (HR, 0.95; 95% CI, 0.87–1.03) was removed from analyses (Supplemental Fig. 1, published on The Endocrine Society's Journals Online web site at <http://jcem.endojournals.org>). Removal of the cluster randomized trial by Law *et al.* (16) showed results similar to the





**FIG. 5.** Trial level meta-analyses (random effect model) of studies included in the IPD analysis (A) and meta-analysis including additional large- and medium-sized studies (B). For studies included in the IPD, all deaths occurring during trials were accounted for as detailed in Table 1.

<sup>1</sup>No between-study heterogeneity was evident for studies on vitamin D with calcium ( $P = 0.46$ ;  $I^2 = 0\%$ ), vitamin D without calcium ( $P = 0.86$ ;  $I^2 = 0\%$ ) or the overall effect ( $P = 0.69$ ;  $I^2 = 0\%$ ). Influence analyses showed no statistically significant effect of treatment if the WHI study (19) (OR, 0.94; 95% CI, 0.86–1.03) or the Larsen *et al.* (13) study (OR, 0.94; 95% CI, 0.86–1.02) was removed from the analysis.

<sup>2</sup>No between-study heterogeneity was evident for studies on vitamin D with calcium ( $P = 0.37$ ;  $I^2 = 8\%$ ), vitamin D without calcium ( $P = 0.30$ ;  $I^2 = 16\%$ ), or the overall effect ( $P = 0.30$ ;  $I^2 = 13\%$ ). Influence analyses showed no effects of removal of studies one by one, except for removal of the Porthouse *et al.* (14) study, leaving a statistically significant ( $P = 0.02$ ) risk estimate for the remaining seven studies (OR, 0.92; 95% CI, 0.87–0.99). Effect size changed slightly by removal of the cluster randomized studies by Larsen *et al.* (13) (OR, 0.95; 95% CI, 0.88–1.04) and by Law *et al.* (16) (OR, 0.96; 95% CI, 0.89–1.03).

overall analysis with no effect of vitamin D alone (Supplemental Fig. 1). Restricting the trial level analysis to include only individually randomized double-blind studies (9, 10, 12, 15, 17–20, 27–32), mortality was reduced overall (OR, 0.94; 95% CI, 0.89–0.99). Stratification by coadministration of calcium showed a significantly ( $P < 0.05$ ) reduced mortality in response to CaD (OR, 0.93; 95% CI, 0.86–1.00), but not with vitamin D alone (OR, 0.95; 95% CI, 0.89–1.03).

## Discussion

In a pooled analysis, including data at the level of the individual from more than 70,000 elderly participants, mortality was significantly reduced during 3 yr of treatment with CaD, whereas vitamin D alone did not affect mortality. These findings were further supported by a trial level meta-analysis.

### Contrast with previous reviews of vitamin D with or without calcium, and calcium alone on mortality

In the 2007 trial level meta-analysis of vitamin D with or without calcium and mortality, including 18 trials without size limit with a total of 57,311 participants, Autier and Gan-

dini (4) found a risk ratio of 0.93 (95% CI, 0.87–0.99). The results did not appear to be influenced by whether calcium was provided or not, dose of vitamin D, or length of follow-up. Our IPD analysis included four large trials not included in the Autier and Gandini review (4). Chung *et al.* (2) updated the Autier and Gandini review (4) but used different inclusion criteria and found a risk ratio of 0.97 (95% CI, 0.92–1.02) for vitamin D alone (13,833 participants, four trials) and a risk ratio of 0.93 (95% CI, 0.86–1.01) for CaD (44,688 participants, 11 trials). Thus, although their results were not statistically significant for any comparison, the trends were similar to those found here. In accordance with our results, in the 2009 Cochrane review of vitamin D for the prevention of fractures only, the risk ratio for mortality was 1.01 (95% CI, 0.95–1.06) for vitamin D trials with statistical evidence of heterogeneity ( $P_{\text{heterogeneity}} = 0.04$ ;  $I^2 = 68\%$ ) and 0.94 (95% CI, 0.89–0.99) for trials with CaD, with little statistical evidence for heterogeneity of effect ( $P_{\text{heterogeneity}} = 0.70$ ;  $I^2 = 0\%$ ) (5).

### Contrast between vitamin D plus calcium and vitamin D alone results

Reduced mortality with CaD, but not with vitamin D alone could suggest that the reduced mortality is due to an

effect of calcium rather than vitamin D. However, two recent IPD analyses and trial level meta-analyses by Bolland *et al.* (23, 33) show an increased risk of myocardial infarction with calcium, with or without vitamin D. So how can CaD reduce mortality when vitamin D alone appears not to be an influence and calcium alone may increase cardiovascular morbidity? There are several possible explanations. First, the reported 30% increase in myocardial infarction from calcium supplementation would have only a small effect on overall mortality (23). For example, in the United Kingdom, myocardial infarction is responsible for 6.4% of all deaths in women over 75 yr of age; thus, a 30% increase in mortality would have a very small effect on overall mortality (19). Secondly, competing risks for disease may be another explanation. Calcium supplementation could reduce recurrence of colorectal adenomas and thus colorectal cancer and mortality (34), an effect that may be strengthened if vitamin D is also provided (35). Calcium and vitamin D may reduce the risk of cancer, particularly breast and colorectal cancer (36). Calcium supplementation has some effect in preventing osteoporotic fractures, although probably not hip fractures, the most important direct cause of osteoporosis mortality (37). However, because we adjusted for incident hip and spine fractures, the reduced mortality in our analysis is most likely not attributable to a lower risk of fracture (and deaths after fractures). Thirdly, CaD may have effects when given together greater than their individual effects. Several studies have shown associations between high plasma levels of PTH and the risk of different (including cardiovascular) diseases and mortality (38, 39). Calcium, as well as vitamin D, is known to lower PTH levels. The doses of vitamin D tested in the vitamin D-alone studies were possibly too low to affect PTH levels, whereas PTH levels were lowered in response to CaD. Because PTH levels were not measured systematically in the included trials, we were unable to test this hypothesis. Fourthly, the vitamin D trials may have selected doses and methods of administration that were not adequate; in addition, the participants included in the vitamin D-alone trials were older than those included in the CaD trials. Our data do not exclude that treatment (vitamin D with or without calcium) is only effective in the early stages of a disease. Finally, differences in the ascertainment of events between the Bolland *et al.* (23, 33) meta-analyses and the robust ascertainment of death might be another explanation.

Hazard rates started to diverge quite quickly in our IPD analysis, as shown in Figs. 1 and 2. Unfortunately, we were unable to evaluate the causes of death in response to the use of supplements. Epidemiological studies have suggested that vitamin D and calcium may affect many dif-

ferent organ systems and health outcomes, including infections, cardiovascular health, autoimmune diseases, and malignancies (3). Our analyses suggest that supplementation with CaD starts to affect general health early, which is sustained during long-term treatment. Our data do not allow for conclusions on whether this is due to an immediate and sustained effect or whether harm/benefit ratios for certain health outcomes change over time.

### Limitations of our analysis

Although it contributes a systematic appraisal of important confounders that may contribute to the difference in survival effects found in clinical trials, the present analysis has important limitations.

Overall, despite a large sample size, the IPD analysis cannot correct potential flaws of the original studies, *e.g.* in design and compliance with medication. Additional limitations are imposed by the limited set of variables that had been addressed in a fairly consistent way across studies. In general, large CaD trials have been conducted with limited funding, and this imposed limitations on the number of variables that could be collected and the degree of adjudication on exposures and outcomes performed. Although vitamin D can be split into two dose groups (about 10  $\mu\text{g}/\text{d}$  and about 20  $\mu\text{g}/\text{d}$ , respectively), and some studies gave calcium whereas others did not, the pooled study population does not create a true factorial design of four study arms well matched for age, sex, and risk factors. For example, only the RECORD study (15)—a tertiary prevention study for osteoporosis, because all patients had prior fractures—used daily oral vitamin D at the 20  $\mu\text{g}/\text{d}$  dose without calcium. It is possible that the lack of effect in the patient level analysis regarding vitamin D given alone is influenced more by the design of the trials than by the active intervention itself. Of the four studies, the Smith *et al.* (18) and Sanders *et al.* (20) studies (once yearly high-dose treatment) may have been influenced by too high and long a dosing interval, the RECORD study (15) by the use of calcium in the control arm and poorer compliance, and the Meyer study (11) by the low dose of vitamin D. Our findings showed a significantly reduced mortality if CaD was administered daily, whereas no effect was evident if vitamin D was administered intermittently. However, because the test on interaction between daily *vs.* intermittent administration was insignificant, our data do not exclude that the lack of an effect may be due to an insufficient statistical power, *e.g.* too few participants in the group receiving vitamin D intermittently. Several of the risk estimates on the effects of vitamin D alone were below 1.00, with an upper limit of the CI only slightly above 1.00, which may indicate potential beneficial effects of vitamin D alone. However, because the results did not

reach strict statistical significance, we think that our results should only be interpreted in such a way that they should encourage further exploration of whether such effects are present.

In the IPD analysis, information on adherence, self-administered CaD supplements, and baseline dietary calcium and vitamin D intake was not consistently available, so this could not be accurately addressed. Accordingly, we were not able to perform a per-protocol analysis. However, our intention-to-treat analytical approach probably offers a more realistic measure of what can be achieved by applying such measures in the general population of elderly participants at risk of fracture than more intensive studies. In accordance, we chose to include all randomized studies in our primary analyses independently of the nature of randomization. Although cluster randomized studies may be prone, for example, to selection bias (40), the less rigorous design may more accurately reflect the real-world circumstances because study participants are normally not required to fulfill a number of individual criteria for participation. Nevertheless, analyses including only individually randomized controlled studies showed results similar to the overall analyses, indicating that inclusion of non-individually randomized studies did not change the overall findings. An additional limitation in the IPD analysis was the restricted time frame of 3 yr. Nevertheless, extending our IPD analysis to include all deaths occurring during the entire duration of the eight trials did not change the overall results, which was further supported by the trial level meta-analysis for all deaths during the entire duration of the trials.

Within the CaD trials, a significantly reduced mortality was only shown for the low dose of vitamin D. Our analyses did not indicate that a higher dose ( $\geq 20$   $\mu\text{g}/\text{d}$ ) is inferior to a lower daily dose. Rather, most risk estimates on a daily dose of at least 20  $\mu\text{g}$  of vitamin D alone were lower than with a daily dose of 10  $\mu\text{g}$ . In addition to differences in average age between studies on effects of CaD or vitamin D alone, it should be emphasized that the primary endpoint in all studies was fracture prevention and that the different studies included different groups of participants. In some studies, effects of supplements were studied in the general population of elderly participants (13, 18–21), whereas other studies investigated supplements for secondary (11, 14) or tertiary (15) fracture prophylaxis. Vitamin D status before study entry may have differed between studies, and effects of vitamin D supplementation with or without calcium may depend on vitamin D status (and daily calcium intake). We cannot exclude the possibility that such characteristics, inherited in the design of the original studies, may affect mortality and may have influenced effects of vitamin D (and calcium). Epidemio-

logical studies have suggested that mortality may be increased in participants with low vitamin D levels, although high levels could be harmful as well (41). It remains unknown whether this is due to the biological effect of vitamin D or due to confounders that it may not be possible to adjust fully for in epidemiological studies. Because plasma 25-hydroxyvitamin D levels were not measured and calcium intake was not assessed consistently at baseline or during follow-up in the trials included, unfortunately our data do not allow for further clarification on this matter.

In our study, we adjusted for incident fractures during trials to assess effects beyond an effect due to a reduced mortality caused by fewer fractures in response to treatment. Interestingly, antiresorptive treatments with bisphosphonates, strontium ranelate, or denosumab have been shown to reduce mortality, often to a greater extent than is explained by the reduction in fracture risk (42). Further studies are needed to investigate possible interrelationships between these findings.

In conclusion, our IPD analysis and trial level meta-analysis consistently showed reduced mortality in elderly participants randomized to vitamin D supplements in combination with calcium, whereas the analyses based on existing interventions and trial populations did not support an effect of vitamin D alone. Accordingly, calcium with vitamin D supplementation to elderly participants is overall not harmful to survival, and may have beneficial effects on general health.

## Acknowledgments

We are grateful to the authors of the original trial reports, including Guro B. Smedshaug, Elisabeth Kvaavik, Jan A. Falch, Aage Tverdal, Jan I. Pedersen, Erik Roy Larsen, Anders Foldspang, Geoff Nicholson, Amanda Stuart, Elizabeth Williamson, Graeme MacLennan, Alison M. McDonald, Gladys C. McPherson, Adrian M. Grant, Marion K. Campbell, Helen Raphael, Sarah Crozier, Paul Maslin, Marjo Tuppurainen, Matti Karkkainen, Toni Rikkinen, Lorenzo Sandini, Joonas Sirola, Risto Honkanen, Esko Alhava, and Heikki Kroger. The authors thank the WHI investigators and staff for their dedication, and the study participants for making the program possible. A full listing of WHI investigators can be found at: <https://cleo.whi.org/researchers/Documents%20%20Write%20a%20Paper/WHI%20Investigator%20Short%20List.pdf>.

Address all correspondence and requests for reprints to: Lars Rejnmark, M.D., Ph.D., Dr.Med.Sc., Associate Professor of Endocrinology, Aarhus University, Department of Endocrinology and Internal Medicine, Aarhus Sygehus, Aarhus University Hospital, Tage-Hansens gade 2, DK 8000 Aarhus C, Denmark. E-mail: [rejmark@post6.tele.dk](mailto:rejmark@post6.tele.dk).

The WHI program is funded by the National Heart, Lung, and Blood Institute, National Institutes of Health, U.S. Department of Health and Human Services through contracts

N01WH22110, 24152, 32100-2, 32105-6, 32108-9, 32111-13, 32115, 32118-32119, 32122, 42107-26, 42129-32, and 44221. K.M.S. acknowledges funding through the National Health and Medical Research Council, Australia, with supplemental funding from the Australian Commonwealth Department of Health and Ageing. L.R. acknowledges personal funding (Grant 09-070940) from the Danish Council for Independent Research in Medical Sciences. A.A. acknowledges personal funding from the UK Medical Research Council and the Chief Scientist Office of the Scottish Government Health Directorates. L.M. acknowledges support from the Danish Osteoporosis Association, The Municipality of the City of Randers, Randers Central Hospital, Aarhus County, Denmark, and The Pharmacy Association of 1991. The Health Services Research Unit, University of Aberdeen, is funded by the Chief Scientist Office of the Scottish Government Health Directorates. No funding source had influence on the present paper.

**Author Contributions:** L.R. is guarantor, had full access to all the data in the study, and takes responsibility for the management of the data received from the primary trials and the accuracy of the data analysis. L.R., B.A., A.A., T.M., K.B., H.E.M., J.A.R., L.M., and R.M.F. conceived and designed the study. L.R. and B.A. acquired and analyzed the data. L.R., B.A., T.M., A.A., L.M., and R.M.F. wrote the manuscript. All authors contributed to revising the manuscript critically and approved the final version, as well as contributing to the interpretation of the joint results and to the design of their individual trials.

**Disclosure Summary:** L.R. has received speakers' fees from Bristol-Myers Squibb and Eli Lilly. A.A. had study drugs for clinical trials of vitamin D and calcium supplementation supplied by Shire Pharmaceuticals and Nycomed. T.M. has served on advisory boards for Shire and has received lecture fees from Shire and Strakan Pharmaceuticals. L.M. had free study drugs of vitamin D and calcium supplied by Nycomed DAK. R.M.F. has served as an adviser to Nycomed, Shire, and Prostrakan, all of whom market calcium and vitamin D supplements. H.E.M. participates in a clinical trial of vitamin D supplementation sponsored by the University of Oslo and The Norwegian Women's Public Health Association. The study is also supported by Fürst Medisinsk Laboratorium and Nycomed, including free study drugs. J.E.M. and colleagues at Brigham and Women's Hospital, Harvard Medical School, are recipients of funding from the National Institutes of Health to conduct the VITamin D and Omega-3 Trial (VITAL), a large-scale randomized trial of vitamin D and omega-3 in the prevention of cancer and cardiovascular disease. C.C. has undertaken lecturing and consulting for Shire Pharmaceuticals and Nycomed. F.A. has had study drugs for clinical trials of vitamin D and calcium supplementation supplied by Shire Pharmaceuticals and Nycomed, and has undertaken lecturing and consulting for the same companies. K.B. has served on an advisory board for Osteologic, Servier and Amgen, received research grants from MSD, and served on speakers bureau for Servier, Amgen, and GSK. B.A. has received consultancy fees from Nycomed, Amgen, and Novartis; research grants from Roche and Amgen; and speakers' fees from Servier, Eli Lilly, and MSD. D.T. had study drugs for clinical trials of vitamin D and calcium supplementation supplied by Shire Pharmaceuticals. There were no conflicts of interest for E.T.J., H.E.S., K.S., J.A.R., K.M.S., and R.D.J.

## References

1. Freedman DM, Looker AC, Abnet CC, Linet MS, Graubard BI 2010 Serum 25-hydroxyvitamin D and cancer mortality in the NHANES III Study (1988–2006). *Cancer Res* 70:8587–8597
2. Chung M, Balk EM, Brendel M, Ip S, Lau J, Lee J, Lichtenstein A, Patel K, Raman G, Tatsioni A, Terasawa T, Trikalinos TA 2009 Vitamin D and calcium: a systematic review of health outcomes. *Evid Rep Technol Assess (Full Rep)* 183:1–420
3. 2011 Dietary reference intakes for calcium and vitamin D. Washington, DC: Institute of Medicine
4. Autier P, Gandini S 2007 Vitamin D supplementation and total mortality: a meta-analysis of randomized controlled trials. *Arch Intern Med* 167:1730–1737
5. Avenell A, Gillespie WJ, Gillespie LD, O'Connell D 2009 Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis. *Cochrane Database Syst Rev* 2:CD000227
6. Bjelakovic G, Glud LL, Nikolova D, Whitfield K, Wetterslev J, Simonetti RG, Bjelakovic M, Glud C 2011 Vitamin D supplementation for prevention of mortality in adults. *Cochrane Database Syst Rev* 7:CD007470
7. Lambert PC, Sutton AJ, Abrams KR, Jones DR 2002 A comparison of summary patient-level covariates in meta-regression with individual patient data meta-analysis. *J Clin Epidemiol* 55:86–94
8. D.I.P.A.R.T. group, Abrahamsen B, Masud T, Avenell A, Anderson F, Meyer HE, Cooper C, Smith H, LaCroix AZ, Torgerson D, Johansen A, Jackson R, Rejnmark L, Wactawski-Wende J, Brixen K, Mosekilde L, Robbins JA, Francis RM 2010 Patient level pooled analysis of 68,500 patients from seven major vitamin D fracture trials in US and Europe. *BMJ* 340:b5463
9. Chapuy MC, Arlot ME, Delmas PD, Meunier PJ 1994 Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women. *BMJ* 308:1081–1082
10. Lips P, Graafmans WC, Ooms ME, Bezemer PD, Bouter LM 1996 Vitamin D supplementation and fracture incidence in elderly persons. A randomized, placebo-controlled clinical trial. *Ann Intern Med* 124:400–406
11. Meyer HE, Smedshaug GB, Kvaavik E, Falch JA, Tverdal A, Pedersen JI 2002 Can vitamin D supplementation reduce the risk of fracture in the elderly? A randomized controlled trial. *J Bone Miner Res* 17:709–715
12. Trivedi DP, Doll R, Khaw KT 2003 Effect of four-monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial. *BMJ* 326:469
13. Larsen ER, Mosekilde L, Foldspang A 2004 Vitamin D and calcium supplementation prevents osteoporotic fractures in elderly community dwelling residents: a pragmatic population-based 3-year intervention study. *J Bone Miner Res* 19:370–378
14. Porthouse J, Cockayne S, King C, Saxon L, Steele E, Aspray T, Baverstock M, Birks Y, Dumville J, Francis R, Iglesias C, Puffer S, Sutcliffe A, Watt I, Torgerson DJ 2005 Randomised controlled trial of calcium and supplementation with cholecalciferol (vitamin D3) for prevention of fractures in primary care. *BMJ* 330:1003
15. Grant AM, Avenell A, Campbell MK, McDonald AM, MacLennan GS, McPherson GC, Anderson FH, Cooper C, Francis RM, Donaldson C, Gillespie WJ, Robinson CM, Torgerson DJ, Wallace WA 2005 Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial. *Lancet* 365:1621–1628
16. Law M, Withers H, Morris J, Anderson F 2006 Vitamin D supplementation and the prevention of fractures and falls: results of a randomised trial in elderly people in residential accommodation. *Age Ageing* 35:482–486
17. Lyons RA, Johansen A, Brophy S, Newcombe RG, Phillips CJ, Lervy B, Evans R, Wareham K, Stone MD 2007 Preventing fractures

- among older people living in institutional care: a pragmatic randomised double blind placebo controlled trial of vitamin D supplementation. *Osteoporos Int* 18:811–818
18. Smith H, Anderson F, Raphael H, Maslin P, Crozier S, Cooper C 2007 Effect of annual intramuscular vitamin D on fracture risk in elderly men and women—a population-based, randomized, double-blind, placebo-controlled trial. *Rheumatology (Oxford)* 46:1852–1857
  19. LaCroix AZ, Kotchen J, Anderson G, Brzyski R, Cauley JA, Cummings SR, Gass M, Johnson KC, Ko M, Larson J, Manson JE, Stefanick ML, Wactawski-Wende J 2009 Calcium plus vitamin D supplementation and mortality in postmenopausal women: the Women's Health Initiative Calcium-Vitamin D Randomized Controlled Trial. *J Gerontol A Biol Sci Med Sci* 64:559–567
  20. Sanders KM, Stuart AL, Williamson EJ, Simpson JA, Kotowicz MA, Young D, Nicholson GC 2010 Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial. *JAMA* 303:1815–1822
  21. Salovaara K, Tuppurainen M, Kärkkäinen M, Rikkonen T, Sandini L, Sirola J, Honkanen R, Alhava E, Kröger H 2010 Effect of vitamin D(3) and calcium on fracture risk in 65- to 71-year-old women: a population-based 3-year randomized, controlled trial—the OST-PRE-FPS. *J Bone Miner Res* 25:1487–1495
  22. Romagnoli E, Mascia ML, Cipriani C, Fassino V, Mazzei F, D'Erasmus E, Carnevale V, Scillitani A, Minisola S 2008 Short and long-term variations in serum calcitropic hormones after a single very large dose of ergocalciferol (vitamin D2) or cholecalciferol (vitamin D3) in the elderly. *J Clin Endocrinol Metab* 93:3015–3020
  23. Bolland MJ, Avenell A, Baron JA, Grey A, MacLennan GS, Gamble GD, Reid IR 2010 Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. *BMJ* 341:c3691
  24. Dyer CA, Taylor GJ, Reed M, Dyer CA, Robertson DR, Harrington R 2004 Falls prevention in residential care homes: a randomised controlled trial. *Age Ageing* 33:596–602
  25. Higgins JPT, Green S 2006 Cluster-randomized trials. *Cochrane Handbook for Systematic Reviews of Interventions* 4.2.6, Section 8.11.2. Issue 4. Chichester, UK: The Cochrane Collaboration
  26. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group 2009 Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med* 6:e1000097
  27. Chapuy MC, Pamphile R, Paris E, Kempf C, Schlichting M, Arnaud S, Garnero P, Meunier PJ 2002 Combined calcium and vitamin D3 supplementation in elderly women: confirmation of reversal of secondary hyperparathyroidism and hip fracture risk: the Decalys II study. *Osteoporos Int* 13:257–264
  28. Flicker L, MacInnis RJ, Stein MS, Scherer SC, Mead KE, Nowson CA, Thomas J, Lowndes C, Hopper JL, Wark JD 2005 Should older people in residential care receive vitamin D to prevent falls? Results of a randomized trial. *J Am Geriatr Soc* 53:1881–1888
  29. Baeksgaard L, Andersen KP, Hyldstrup L 1998 Calcium and vitamin D supplementation increases spinal BMD in healthy, postmenopausal women. *Osteoporos Int* 8:255–260
  30. Latham NK, Anderson CS, Lee A, Bennett DA, Moseley A, Cameron ID 2003 A randomized, controlled trial of quadriceps resistance exercise and vitamin D in frail older people: the Frailty Interventions Trial in Elderly Subjects (FITNESS). *J Am Geriatr Soc* 51:291–299
  31. Brazier M, Grados F, Kamel S, Mathieu M, Morel A, Maamer M, Sebert JL, Fardellone P 2005 Clinical and laboratory safety of one year's use of a combination calcium + vitamin D tablet in ambulatory elderly women with vitamin D insufficiency: results of a multicenter, randomized, double-blind, placebo-controlled study. *Clin Ther* 27:1885–1893
  32. Schleithoff SS, Zittermann A, Tenderich G, Berthold HK, Stehle P, Koerfer R 2006 Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double-blind, randomized, placebo-controlled trial. *Am J Clin Nutr* 83:754–759
  33. Bolland MJ, Grey A, Avenell A, Gamble GD, Reid IR 2011 Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women's Health Initiative limited access dataset and meta-analysis. *BMJ* 342:d2040
  34. Weingarten MA, Zalmanovici A, Yaphe J 2008 Dietary calcium supplementation for preventing colorectal cancer and adenomatous polyps. *Cochrane Database Syst Rev* 1:CD003548
  35. Jacobs ET, Jurutka PW, Martinez ME, Alberts DS 2009 Vitamin D, calcium, and colorectal neoplasia: new insights on mechanisms of action. *Cancer Prev Res (Phila)* 2:197–199
  36. Bolland MJ, Grey A, Gamble GD, Reid IR 2011 Calcium and vitamin D supplements and health outcomes: a reanalysis of the Women's Health Initiative (WHI) limited-access data set. *Am J Clin Nutr* 94:1144–1149
  37. Reid IR, Bolland MJ, Grey A 2008 Effect of calcium supplementation on hip fractures. *Osteoporos Int* 19:1119–1123
  38. Hagström E, Hellman P, Larsson TE, Ingelsson E, Berglund L, Sundström J, Melhus H, Held C, Lind L, Michaëlsson K, Arnlöv J 2009 Plasma parathyroid hormone and the risk of cardiovascular mortality in the community. *Circulation* 119:2765–2771
  39. Chen JS, Sambrook PN, March L, Cameron ID, Cumming RG, Simpson JM, Seibel MJ 2008 Hypovitaminosis D and parathyroid hormone response in the elderly: effects on bone turnover and mortality. *Clin Endocrinol (Oxf)* 68:290–298
  40. Torgerson DJ 2001 Contamination in trials: is cluster randomisation the answer? *BMJ* 322:355–357
  41. Melamed ML, Michos ED, Post W, Astor B 2008 25-Hydroxyvitamin D levels and the risk of mortality in the general population. *Arch Intern Med* 168:1629–1637
  42. Bolland MJ, Grey AB, Gamble GD, Reid IR 2010 Effect of osteoporosis treatment on mortality: a meta-analysis. *J Clin Endocrinol Metab* 95:1174–1181
  43. Krieg MA, Jacquet AF, Bremgartner M, Cuttelod S, Thiébaud D, Burckhardt P 1999 Effect of supplementation with vitamin D3 and calcium on quantitative ultrasound of bone in elderly institutionalized women: a longitudinal study. *Osteoporos Int* 9:483–488
  44. Komulainen M, Kröger H, Tuppurainen MT, Heikkinen AM, Alhava E, Honkanen R, Jurvelin J, Saarikoski S 1999 Prevention of femoral and lumbar bone loss with hormone replacement therapy and vitamin D3 in early postmenopausal women: a population-based 5-year randomized trial. *J Clin Endocrinol Metab* 84:546–552
  45. Avenell A, Grant AM, McGee M, McPherson G, Campbell MK, McGee MA, RECORD Trial Management Group 2004 The effects of an open design on trial participant recruitment, compliance and retention—a randomized controlled trial comparison with a blinded, placebo-controlled design. *Clin Trials* 1:490–498
  46. Harwood RH, Sahota O, Gaynor K, Masud T, Hosking DJ 2004 A randomised, controlled comparison of different calcium and vitamin D supplementation regimens in elderly women after hip fracture: the Nottingham Neck of Femur (NONOF) Study. *Age Ageing* 33:45–51
  47. Meier C, Woitge HW, Witte K, Lemmer B, Seibel MJ 2004 Supplementation with oral vitamin D3 and calcium during winter prevents seasonal bone loss: a randomized controlled open-label prospective trial. *J Bone Miner Res* 19:1221–1230